Given that it is best known for its aesthetic potential in reducing facial wrinkles, few people will know that Botox (onabotulinumtoxinA) has as many as 11 separate therapeutic indications, treating conditions ranging from overactive bladder to chronic migraines.
Fewer people still will be aware that Botox is being investigated as a treatment for major depressive disorder (MDD), with early results suggesting that injecting the neurotoxic protein into the glabella area can have highly promising results even in patients with treatment-resistant depression.
What is clear is that Ireland-incorporated drugmaker Allergan (NYSE: AGN) is making the most of what it one of its flagship products, and that it is not finished there, as shown by its investigations in depression, an area of limited progress in recent decades.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze